Provided by Tiger Trade Technology Pte. Ltd.

Orchestra BioMed

6.12
+0.31005.34%
Post-market: 6.11-0.0099-0.16%16:54 EDT
Volume:464.42K
Turnover:2.80M
Market Cap:366.47M
PE:-6.12
High:6.25
Open:5.87
Low:5.76
Close:5.81
52wk High:6.25
52wk Low:2.20
Shares:59.88M
Float Shares:33.00M
Volume Ratio:1.09
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9995
EPS(LYR):-1.1091
ROE:-397.30%
ROA:-45.73%
PB:18.97
PE(LYR):-5.52

Loading ...

Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Orchestra BioMed Holdings (OBIO)

TIPRANKS
·
May 12

Orchestra BioMed gives clinical, regulatory update on BACKBEAT trial timeline

TIPRANKS
·
May 12

Orchestra BioMed targets BACKBEAT trial enrollment completion by end-Q3 2026

Reuters
·
May 12

U.S. Earnings Preview: After Market Close May 8

Dow Jones
·
May 09

Orchestra BioMed receives $15M payment from Ligand

TIPRANKS
·
May 07

Press Release: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Dow Jones
·
May 06

Orchestra Biomed Receives $20 Million Payment From Medtronic Under Previously Announced Financing Agreement

THOMSON REUTERS
·
May 06

Orchestra Biomed Holdings Inc expected to post a loss of 43 cents a share - Earnings Preview

Reuters
·
May 02

Orchestra granted additional breakthrough device designation for AVIM therapy

TIPRANKS
·
May 01

Orchestra BioMed wins FDA Breakthrough Device designation for AVIM hypertension therapy

Reuters
·
Apr 30

FDA Grants Orchestra Biomed Additional Breakthrough Device Designation for Avim Therapy

THOMSON REUTERS
·
Apr 30

RTW Investments reports disposal of 32 Orchestra BioMed shares for $132.16

Reuters
·
Apr 30

Orchestra BioMed says MODERATO II trial shows 13.2 mmHg AVIM blood pressure drop

Reuters
·
Apr 24

Orchestra BioMed presentation highlights pivotal trials for hypertension pacing, sirolimus artery therapy

Reuters
·
Apr 06

Orchestra BioMed publishes corporate deck highlighting pivotal AVIM hypertension, Virtue SAB artery disease trials

Reuters
·
Mar 30

Orchestra BioMed Publishes CRT 2026 AVIM Therapy Presentation

Reuters
·
Mar 24

Analysts’ Top Healthcare Picks: Orchestra BioMed Holdings (OBIO), Cardinal Health (CAH)

TIPRANKS
·
Mar 18

Orchestra BioMed CEO and Chairperson David P. Hochman acquires USD 42,900 in common shares

Reuters
·
Mar 17